High Proportions of Patients With Advanced HIV Are Antiretroviral Therapy Experienced: Hospitalization Outcomes From 2 Sub-Saharan African Sites

Janet Ousley, Aline Aurore Nyibizi, Stephen Wanjala, Alexandra Vandenbulcke, Beatrice Kirubi, Willis Omwoyo, Janthimala Price, Leon Salumu, Elisabeth Szumilin, Sofie Spiers, Gilles van Cutsem, Maria Mashako, Freddy Mangana, Ramzia Moudarichirou, Rebecca Harrison, Tony Kalwawingila, Gisele Lumowo, Vincent Lambert, and David Maman

1Médecins Sans Frontières, Paris, France; 2Médecins Sans Frontières, Brussels, Belgium; and 3Epicentre, Paris, France

**Background.** Human immunodeficiency virus (HIV) remains an important cause of hospitalization and death in low- and middle-income countries. Yet morbidity and in-hospital mortality patterns remain poorly characterized, with prior antiretroviral therapy (ART) exposure and treatment failure status largely unknown.

**Methods.** We studied HIV-infected inpatients aged ≥13 years from cohorts in Kenya and the Democratic Republic of Congo (DRC), assessing clinical and demographic characteristics and hospitalization outcomes. Kenyan inpatients were prospectively enrolled during hospitalization; identical retrospective data were extracted for Congolese patients meeting the study criteria using routine medical information.

**Results.** Among 338 HIV-infected patients in Kenya and 411 in DRC, 83.7% (95% confidence interval [CI], 79.4%–87.3%) and 97.3% (95% CI, 95.2%–98.5%), were admitted with advanced disease (defined as CD4 <200 cells/µL or World Health Organization stage 3/4 illness). Among inpatients with advanced HIV, 35.4% and 21.7% were ART-naive at admission. Patients under care had a median time of 44.1 (interquartile range [IQR], 18.4–90.5) months and 55.9 (IQR, 28.1–99.6) months on treatment; 17.2% (95% CI, 13.5%–21.6%) and 29.6% (95% CI, 25.4%–34.3%) died, 25.9% (95% CI, 16.0%–39.0%) and 22.5% (95% CI, 15.8%–31.0%) of these within 48 hours.

**Conclusions.** Across 2 diverse clinical contexts in sub-Saharan Africa, advanced HIV inpatients were frequently admitted with low CD4 counts, often failing first-line ART. Earlier identification of treatment failure and rapid switching to second-line ART are needed.

**Keywords.** Kenya; Democratic Republic of Congo; treatment failure.

Human immunodeficiency virus (HIV) persists as a major cause of hospitalization and in-hospital mortality in low- and middle-income countries (LMICs), where much of the world's HIV prevalence occurs [1, 2]. Despite having increased access to antiretroviral therapy (ART) for more than a decade in these countries, many HIV-infected inpatients continue to present late to care with advanced disease (defined as a CD4 count <200 cells/µL or World Health Organization [WHO] stage 3/4 illness) after having never sought testing or initiated ART [3, 4]. Others are hospitalized after years on ART and are admitted in a state of clinical, immunologic, and virologic failure, with disease that is resistant to ART due to myriad factors that often include drug adherence challenges, which prevent consistent access to and use of HIV therapies. Indeed, studies have shown that up to 25% of patients will interrupt their treatment at some point [5].

Morbidity and mortality among hospitalized patients with advanced HIV remain poorly understood in settings with few laboratory or diagnostic resources, with little evidence characterizing these patients’ prior ART exposure and treatment failure status [6]. To better understand these patients, we performed separate hospital-based analyses of HIV-infected individuals admitted to inpatient departments in facilities supported by Médecins Sans Frontières (MSF) in 2 different settings in Kenya and the Democratic Republic of Congo (DRC).

**METHODS**

**Study Setting**

This operational cohort study was conducted at 2 live clinical sites using medical data from inpatient departments in MSF-supported hospital wards. In Kenya, Homa-Bay County (HBC) has the highest adult HIV prevalence in the country (27.1%) and one of the highest rates in the world [7]. As the first place in

Correspondence: J. Ousley, Médecins Sans Frontières, 40 Rector St, New York, NY 10006 (janet.ousley@newyork.msf.org).

Clinical Infectious Diseases® 2018;66(S2):S126–32

2018 World Health Organization; licensee Oxford University Press USA. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article’s original URL. DOI: 10.1093/cid/ciy103

S126 • CID 2018:66 (Suppl 2) • Ousley et al
RNA was quantified as part of routine care in Kinshasa with Kinshasa. For patients with suspected treatment failure, HIV-1 Pima PoC test (Alere Health sprl, St Denis, Belgium) in Kenya cerebrospinal fluid. CD4 cell counts were determined by Alere ernal flow assay was used to detect Rapid Diagnostic Test, and cryptococcal antigen (CrAg) lat ing. Malaria antigens were investigated using the SD Bioline or urine lipoarabinomannan assay (TB-LAM) for rapid test or GeneExpert RIF/MTB (Cepheid, Sunnyvale, California) for ART (including those with and without a prior HIV diagnosis) or infections, and viremia. Clinical and immunological failures were described using WHO definitions. Aggregate measures were not calculated and comparative analysis between the 2 sites was not conducted.

Ethics Committee Approval
In Kenya, ethics approval was granted from the Kenya Medical Research Institute national research committee (protocol number 450). Each participant (or their guardian if incapacitated) provided written consent to participate to the study. In DRC, the Kinshasa Ethical Review Board (ERB) of the Ministry of Health provided approval of study protocols and procedures, but verbal consent from patients was not sought for the retrospective analysis of routinely collected, anonymized data. MSF’s organizational Ethics Review Board provided additional review of both sites’ study procedures.

RESULTS
Baseline Clinical Characteristics
Demographic and clinical characteristics of 338 HIV-infected patients in Kenya and 411 HIV patients in DRC (median CD4 at presentation, 122 [IQR, 44.5–323] cells/µL and 68.5 cells/µL [IQR, 23–215], respectively) are shown in Table 1. Of these, 83.7% and 97.3% were admitted with advanced disease, among whom 45.3% and 54.3%, respectively, were admitted with a CD4 count of <100 cells/µL. More Kenyan men than women presented with advanced disease (80.0% vs 68.0%, \( P = 0.02 \)) with substantially lower median CD4 counts (93 [IQR, 42–234] cells/µL vs 172 [IQR, 46–409] cells/µL for women). In DRC, no gender differences were seen. Of all HIV-infected inpatients, 53.2% and 43.6% were “late presenters,” defined as individuals who had either never initiated ART (including those with and without a prior HIV diagnosis) or who had only recently initiated treatment (<6 months on ART). Late presenters are further characterized in Tables 1–3.
Among Kenyan and Congolese patients, 35.3% and 21.8%, respectively, were ART naive at admission. Among those on ART >6 months at admission (46.8% and 56.4%), patients had a median time of 44.1 months [IQR, 18.4–90.5] and 55.9 [IQR, 28.1–99.6] months on treatment in Kenya and DRC, respectively. Overall, patients were hospitalized for a median of 6 days in both sites. Median CD4 counts were no different in Kenya (114 [IQR, 36–309] cells/µL in ART experienced vs 129 [IQR, 46–337] cells/µL in ART naive) and higher in DRC among the ART-experienced patients (84 [IQR, 22–239] cells/µL vs 47 [IQR, 22–123] cells/µL). Of Kenyan patients, 26.9% ever had tuberculosis and 9.8% were on TB treatment at admission. In DRC, 27.7% ever had tuberculosis and 28.2% were on TB treatment at admission.

**Nonnucleoside Reverse Transcriptase Inhibitor First-line Treatment Failure**

Among patients on ART for >6 months, 93.2% and 74.3% were on nonnucleoside reverse transcriptase inhibitor–based regimens in Kenya and DRC, respectively. Patients admitted to care in a state of clinical (WHO stage 3/4), immunological (CD4 count <100 cells/µL plus ART >6 months), or virological failure (VL >1000 copies/mL) are detailed in Table 1.

**Morbidity**

Primary coinfections and case fatality rates for each morbidity are characterized in Table 2. Comorbidity was associated with lower CD4 levels at admission, especially among those with TB. Infectious illness caused most hospitalization: TB (13.3%; median hospitalization of 6 days), malaria (11.6%; 3.5 days), pneumonia (8.9%; 5 days), gastroenteritis (9.9%; 6 days), and neurological infections (toxoplasmosis, cryptococcal meningitis [CCM], and meningitis) were principal infections in Kenya. In Kinshasa, TB (67.2%; 7 days), malaria (16.1%; 5 days), toxoplasmosis (17.1%; 7.5 days), CCM (9.4%; 9.5 days), and pneumocystis pneumonia (8.7%; 10 days) were most frequent.

---

### Table 1. Comparison of Sociodemographic and Clinical Characteristics Between Antiretroviral Therapy (ART)–Naive and ART-Experienced Human Immunodeficiency Virus–Infected Inpatients at Admission

| Characteristic | Kenya (n = 331) | DRC (n = 376) |
|---------------|----------------|--------------|
| **Late Presenters** | | |
| No Prior ART | ART <6 mo | ART >6 mo | No Prior ART | ART <6 mo | ART >6 mo |
| Age, y | | | | | | |
| 13–29 | 51 (43.6) | 20 (33.9) | 42 (27.1) | 17 (20.7) | 4 (4.9) | 36 (17.1) |
| 30–49 | 55 (47.0) | 33 (55.9) | 85 (54.8) | 52 (63.4) | 56 (68.3) | 127 (60.2) |
| >50 | 11 (9.4) | 6 (10.1) | 28 (18.1) | 13 (15.9) | 22 (26.8) | 48 (22.8) |
| Sex | | | | | | |
| Male | 50 (42.7) | 33 (55.9) | 78 (50.3) | 27 (33.3) | 29 (35.4) | 67 (31.6) |
| Female | 67 (53.3) | 26 (44.1) | 77 (49.7) | 54 (66.7) | 53 (64.6) | 145 (68.4) |
| WHO stage | | | | | | |
| 1/2 | 46 (39.2) | 10 (17.0) | 30 (19.5) | 3 (3.8) | 2 (2.5) | 6 (3.0) |
| 3/4 | 71 (60.6) | 124 (80.0) | 124 (80.5) | 76 (96.2) | 79 (97.5) | 193 (97.0) |
| CD4 count, cells/µL | | | | | | |
| >500 | 25 (21.4) | 4 (6.8) | 19 (12.3) | 4 (5.2) | 3 (4.0) | 10 (5.2) |
| 200–499 | 22 (18.7) | 14 (23.7) | 35 (22.5) | 12 (15.6) | 17 (22.7) | 47 (24.6) |
| 100–199 | 18 (15.3) | 11 (18.6) | 29 (18.7) | 5 (6.5) | 12 (16.0) | 32 (16.8) |
| <100 | 51 (43.6) | 30 (50.8) | 71 (45.8) | 56 (72.7) | 43 (57.3) | 102 (53.4) |
| HIV-1 RNA quantification | | | | | | |
| Result available, No. | | | | | | |
| VL >1000 copies/mL | | | | | | |
| Knowledge of HIV status | | | | | | |
| Undiagnosed at admission | 47 (40.1) | ... | ... | 47 (90.4) | 22 (36.7) | 106 (62.0) |
| Treatment interruptions | | | | | | |
| ART regimen | | | | | | |
| NNRTI-based (first line) | ... | 59 | 140 (90.3) | ... | 80 (100) | 156 (75.4) |
| PI-based (second line) | ... | 0 | 15 (9.7) | ... | 0 (0) | 51 (24.6) |
| Total | 117 | 59 | 155 | 82 | 82 | 212 |

Data are presented as No. (%) unless otherwise indicated. Abbreviations: ART, antiretroviral therapy; DRC, Democratic Republic of Congo; HIV, human immunodeficiency virus; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; VL, viral load; WHO, World Health Organization.

aSeven patients in Kenya and 26 in DRC not included in totals because of missing ART start date.
bART-naive late presenters include both those who had and had not been previously diagnosed.
cSelf-reported for any reason including drug toxicity, sociocultural reasons (fear, stigma, etc), stockouts, adherence.
dNot applicable; all patients are diagnosed at admission as it is an HIV hospital only.
Among Kenyan and Congolese HIV patients admitted with TB, median CD4 count at admission was 79 (IQR, 46–227) cells/µL and 63 (IQR, 19–171) cells/µL, respectively. The majority of TB cases were pulmonary in Kenya (70.0%) but extrapulmonary in DRC (80.8%), with most extrapulmonary TB cases manifesting as meningitis (24.0%) and pleural effusions (16.0%) in Kenya and as disseminated (82.5%) and meningitis (14.3%) in DRC. Among CCM patients (n = 20 and n = 39, respectively), all were diagnosed with a median CD4 count of <200 (38 [IQR, 25.5–68.5] cells/µL in Kenya and 43 [IQR, 4–74.5] cells/µL in DRC) and 83.3% and 91.6% of these had a CD4 count of <100 cells/µL.

### Mortality

In both sites, CD4 cell count remained the most significant determinant of mortality for all groups, regardless of sex, age, or type or number of comorbidities (Table 2 and Figure 1). Overall, 17.2% of Kenyan and 29.6% of Congolese HIV-infected inpatients died while hospitalized. Within this group, 22.4% and 25.8% of deaths occurred within 48 hours of admission and 93.1% and 81.2% within 2 weeks. After a median observation time of 9 months, a further 30.4% of Kenyan patients died after being discharged from hospital. Postdischarge information was unavailable in Kinshasa. In both sites, CD4 <50 cells/µL at admission increased the odds of mortality, though men in Kenya (adjusted odds ratio, 3.0 [95% CI, 1.6–6.0]) had an elevated mortality risk that was not seen in Kinshasa.

Tuberculosis, the most common cause of hospitalization, occurred in 21.2% and 67.2% of the patients, and in 36.2% and 74.2% of deaths. Among the extremely immunosuppressed, TB was also by far the largest cause of mortality: 22.4% and 28.3% of deaths were among those admitted with <25 cells/µL, 19.0% and 15.0% among those with 25–49 cells/µL, and 13.8% and 20.0% among those with >350 cells/µL, in Kenya and DRC, respectively (Figure 1). Reduced CD4 count at admission was also associated with those whose TB caused their hospitalization. Beyond TB, neurological infections were the most important causes of death in Kenya and in DRC.

### DISCUSSION

Our findings present 2 diverse inpatient contexts in sub-Saharan Africa where, nevertheless, similar characteristics and outcomes emerged, particularly for those with advanced HIV.

---

**Table 2.** Primary Comorbidities at Admission and Case Fatality Rates Among Antiretroviral Therapy (ART)–Naive and ART-Experienced Human Immunodeficiency Virus–Infected Inpatients

| Comorbidity | Kenya (n = 338) | ART Experienced | DRC (n = 376) | ART Experienced |
|-------------|-----------------|-----------------|--------------|----------------|
|              | Late Presenters* | ART <6 mo | Late Presenters* | ART >6 mo |
| Tuberculosis | 20 (17.1)       | 25.0          | 21 (33.9)     | 28.6          | 38 (24.5) | 26.3 |
| CCM          | 6 (5.1)         | 50.0          | 8 (13.6)      | 25.0          | 10 (6.5) | 20.0 |
| PCP          | 0               | NA            | 0             | NA            | 5 (6.1)  | 60.0 |
| Malaria      | 25 (21.4)       | 0             | 6 (10.2)      | 33.3          | 23 (14.8) | 4.4 |
| Toxoplasmosis| 2 (1.7)         | 0             | NA            | 1 (0.6)       | 0        | 6.9 |
| Kaposi sarcoma | 0             | 2 (1.7)       | 0             | 6 (3.9)       | 33.3     | 4.0 |
| Gastroenteritis | 21 (17.9)    | 19.1          | 10 (16.9)     | 10.0          | 25 (16.1) | 4.0 |
| Bacterial meningitis | 11 (9.4) | 27.3          | 6 (10.2)      | 83.3          | 12 (9.4) | 25.0 |
|              | ART >6 mo       |                |              |               |          |     |
| Tuberculosis | 55 (67.1)       | 30.9          | 63 (76.8)     | 45.9          | 134 (63.2) | 25.0 |
| CCM          | 8 (9.8)         | 12.5          | 8 (9.8)       | 37.5          | 21 (9.9) | 9.5 |
| PCP          | 0               | NA            | 0             | NA            | 5 (6.1)  | 60.0 |
| Malaria      | 12 (14.6)       | 273           | 14 (28.6)     | 28.6          | 34 (16.0) | 23.5 |
| Toxoplasmosis| 19 (23.2)       | 36.8          | 19 (23.2)     | 38.9          | 28 (13.2) | 46.4 |
| Kaposi sarcoma | 2 (2.4)      | 50             | 2 (2.4)       | 50            | 4 (1.9)  | 75.0 |
| Gastroenteritis | 2 (2.4)      | 50             | 2 (2.4)       | 50            | 4 (1.9)  | 75.0 |
| Bacterial meningitis | 11 (9.4) | 27.3          | 6 (10.2)      | 83.3          | 12 (9.4) | 25.0 |

Data are presented as No. (%) unless otherwise indicated. Case fatality rate is defined as fatalities occurring while hospitalized.

Abbreviations: ART, antiretroviral therapy; CCM, cryptococcal meningitis; CFR, case fatality rate; NA, not applicable; PCP, pneumocystis pneumonia.

---

**Table 3.** Comparison of Viremia Among Patients, by Treatment Duration and Clinical/Immunological Characteristics

| Characteristic | Detectable VL (> 1000 Copies/mL) |
|----------------|----------------------------------|
|                | ART Naive (Late Presenters*) | ART <6 mo (Late Presenters*) | ART >6 mo (ART Experienced) |
| Kenyan WHO stage 3 or 4 | NA | NA | 33 (64.7) |
| CD4 count <100 cells/µL | NA | NA | 31 (83.8) |
| DRC WHO stage 3 or 4 | 46 (90.2) | 22 (37.3) | 105 (63.5) |
| CD4 count <100 cells/µL | 35 (92.1) | 13 (43.3) | 67 (80.7) |

Data are presented as No. (%) unless otherwise indicated. Abbreviations: ART, antiretroviral therapy; DRC, Democratic Republic of Congo; NA, not applicable; VL, viral load; WHO, World Health Organization.

*ART-naive late presenters include both those who had and had not been previously diagnosed.

---

**Figure 1**

---

**CID 2018:66 (Suppl 2) • S129**

---

HIV Hospitalization Outcomes From Sub-Saharan Africa • CID 2018:66 (Suppl 2) • S129
HIV-infected inpatients were often hospitalized extremely immunosuppressed (45.9% and 56.6% with CD4 < 100 cells/µL), usually because of HIV-related infectious illnesses that could have been diagnosed prior to hospitalization. The 2 contexts were very different: an urban, private MSF hospital in a low-prevalence, low-ART coverage fragile health system vs a rural, public hospital (supported by MSF) in a high-prevalence, middle-income country with high ART coverage (especially among women). Though the 2 contexts cannot be directly compared, across the 2 settings many patients had prior exposure to ART (only one-third in Kenya and one-quarter in DRC were ART naïve at admission) and were admitted in a state of clinical, immunological, or virological failure (80.5%, 45.8%, and 63.2%, respectively, in Homa-Bay and 97.0%, 53.4%, and 62.0%, respectively, in Kinshasa). Regardless of the sites’ differences, these HIV patients were exposed to health systems that failed to identify and address their worsening conditions. To our knowledge, this is the first analysis to report hospitalization outcomes for adult HIV-infected inpatients from a Kenyan or Congolese setting [10].

In 2015 alone, 1.1 million individuals still died due to AIDS, despite being in an age of free ART that is more available and effective than ever before [11]. The Kenyan and Congolese inpatients studied here were different than patients seen a decade ago in that they were aware of their HIV status (85.6% of Kenyan inpatients) and had significant exposure to ART (often years) [12–14]. This new type of advanced HIV inpatient highlights how much more must be done. Recognizing those with deteriorating conditions earlier and responding to them more quickly (including at the primary care level and in the community where obstacles related to extreme stigma, health literacy, and psychosocial issues persist) could likely prevent many advanced cases. It would also address some of the treatment adherence and retention-in-care issues that cause advanced HIV.

CD4 cell counts at admission remained the single most important predictor of morbidity, mortality, and length of stay in both contexts, confirming research that HIV-infected inpatients admitted with low CD4 die more quickly (up to 15 years shorter life expectancy), more frequently, and with more complicated coinfections [15–19]. Of Kenyan and Congolese patients on ART >6 months, 45.8% and 67.2%, respectively, were admitted in a state of immunological failure, and 80.7% and 83.8% of these patients also had a detectable VL of >1000 copies/mL, suggesting either adherence problems or disease that was already resistant to treatment. Yet, during the course of this research, few patients switched to second-line drugs while hospitalized regardless of their CD4 or VL, often because there was not enough information available about adherence and resistance in these settings. Indeed, research from LMICs overall show that patients may take as long as 21 months to switch even after virologic failure has been confirmed [20].

Direct comparison of these different cohorts should be avoided. Though the data are presented together, complete standardization was limited by data availability and quality in each operational context: Kenyan patients were in a public general hospital whereas Congolese patients were in a specialized HIV facility (though all received MSF’s standard of care), and the data come from slightly different time periods. Other possible residual confounders related to differences in prevalence, ART coverage, health system resources, socioeconomic status, health-seeking behaviors, or even seasonality (particularly in Kenya where patients were largely agrarian) in the 2 sites. VL testing was unavailable for all suspected treatment failures (in Kenya, 59.9% of patients with clinical failure did not have results), and those receiving VL testing may have been selected based on contextual factors. HIV-1 genotyping, and thus conclusions about resistance patterns, were not possible. Finally, inpatients are likely not representative of the larger population where individuals remain undiagnosed, have unequal access to care, or may die in their communities before reaching a health facility.

CONCLUSIONS

The large majority of patients in our cohorts had a prior history of ART treatment when they were admitted to inpatient care. Some of these patients were likely experiencing treatment failure and needed their drug regimen to be quickly changed. Mortality among HIV-infected inpatients was high in both Kenya and the DRC, as many patients presented extremely sick and died often and quickly, often needing intensive care services that were beyond what was available in MSF-supported inpatient departments. MSF-supported hospitals usually have relatively high-quality care, consistent funding and resources, and patients with better access to services and ART. The fact that these results were seen even in MSF’s facilities implies that addressing advanced HIV will demand more: improved identification of treatment failure and symptomatic HIV patients in primary healthcare facilities and in the community, better point-of-care diagnostic technology (eg, TB-LAM and CrAg
tests for opportunistic infections, or oral HIV self-tests), and patient tracing and psychosocial support for people who drop out of care or stop treatment [21]. The need remains for expanded access to routine VL testing to verify patients’ adherence and treatment efficacy, and for CD4 as an indicator of immunocompromise to better target opportunistic infection testing. Hospitals will need adapted clinical and counseling approaches, including more timely identification of treatment failures, adherence issues, and adapted care and prophylaxis protocols. Time is critical and reactivity essential.

Though our cohorts cannot be directly compared to each other or other studies, the trends found in each of these contexts clearly indicate that AIDS deaths still haunt the inpatient wards in these sub-Saharan contexts. Despite impressive investments and advancements against HIV over 3 decades, the fight is not over.

Notes

Author contributions. D. M., A. N., G. v. C., F. M., and S. S. conceived of the study; participated in its design, coordination, and statistical analysis; and drafted the manuscript. J. O. participated in the design and statistical analysis; contributed to the manuscript; and provided technical review of the study and technical review of the manuscript. F. M. participated in the design and data collection of the study and technical review of the manuscript. A. N., B. R., J. P., F. M., R. M., T. K., and G. L. supported data collection, data cleaning, and preliminary analysis. D. M. additionally oversaw the study and provided final technical and editorial review of the manuscript. All other authors provided rigorous technical review.

Financial support. This work was supported by MSF program funds. All authors contributed to this study as part of regular duties as staff with MSF. This supplement was supported by funds from the Bill & Melinda Gates Foundation.

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Supplement sponsorship. This article appears as part of the supplement “Advanced HIV Disease,” sponsored by the World Health Organization.

References

1. World Health Organization. HIV/AIDS fact sheet. 2016. Available at: http://www.who.int/mediacentre/factsheets/fs360/en/. Accessed 7 June 2017.
2. Ford N, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet 2015. doi:10.1016/S2352-3018(15)00137-X.
3. Waldrop G, Doherty M, Vitoria M, Ford N. Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy. Trop Med Int Health 2016; 21:1124–30.
4. Geng EH, Hunt PW, Diero LO, et al. Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc 2011; 14:46.
5. Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. J Acquir Immune Defic Syndr 2015; 69:98–108.
6. Meintjes G, Kerkhoff AD, Burton R, et al. HIV-related medical admissions to a South African district hospital remain frequent despite effective antiretroviral therapy scale-up. Medicine 2015; 94:e2269.
7. Kenyan Ministry of Health National AIDS Control Council. Kenya AIDS response progress report: progress towards zero. 2014. Available at: http://www.unaids.org/sites/default/files/country/documents/KEN_narrative_report_2014.pdf. Accessed 7 June 2017.
8. Kenya Ministry of Health. Kenya HIV county profiles 2016. Available at: http://nacc.or.ke/wp-content/uploads/2016/12/Kenya-HIV-County-Profiles-2016.pdf. Accessed 7 September 2017.
9. World Health Organization. Democratic Republic of Congo: estimated anti-retroviral therapy coverage among people living with HIV, 2015. Global Health Observatory Metadata Registry. Available at: http://apps.who.int/gho/data/view.main.23300?lang=en. Accessed 7 June 2017.
10. Nyandiko WM, Mwangi A, Ayaya SO, et al. Characteristics of HIV-infected children seen in Western Kenya. East Afr Med J 2009; 86:364–73.
11. World Health Organization. HIV/AIDS fact sheet. 2016. Available at: http://www.who.int/mediacentre/factsheets/fs360/en/. Accessed 7 June 2017.
12. Weber R, Ruppik M, Rickenbach M, et al; Swiss HIV Cohort Study (SHCS). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195–207.
13. Palella FJ Jr, Baker RK, Moorman AC, et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27–34.
14. Kim JH, Pevudos G Jr, Gonzalez E, Singh S, Kilayko MC, Sharp V. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART). Infection 2013; 41:545–51.
15. Nakagawa E, Ludwick R, Smith G, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2011; 25:000–000. doi:10.1097/QAD.Ob013e32834dce9.
16. May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV: 1. UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343:d6016.
17. Nsanziana S, Remera E, Kanters S, et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Health 2015; 3:e169–77.
18. Mocroft A, Lundgren JD, Sabin ML, et al; Collaborative of Observational HIV Epidemiological Research Europe (COHERE) Study in EuroCoord. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaborator of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013; 10:e1001510.
19. Fox MP, Sanne IM, Conradie F, et al. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South Africa. AIDS 2010; 24:2041–50.
20. Keiser O, Twywa H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23:1867–4.
21. Rick F, Nishibai AA, Shroufi A, et al. Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: a feasibility study in rural Lesotho. PLoS One 2017; 12:e0183656.